title: Controversies in testosterone supplementation therapy.
abstract: Testosterone has now become one of the most widely used medications throughout the world. The rapid growth of the testosterone market in the past 10 years is due to many factors. We currently have a worldwide aging population. In the US, the number of men 65 years old or older is increasing 2-3 times faster than the number of men younger than 65 years. In addition, poor general health and certain medical conditions such as diabetes/metabolic syndrome (MetS), cardiovascular disease (CVD), and osteoporosis have been associated with low serum testosterone levels. [1],[2],[3] There are now fewer concerns regarding the development of prostate cancer (PCa) after testosterone therapy, making it a more attractive treatment option. Finally, the introduction of different forms of testosterone supplementation therapy (TST) with increased promotion, marketing, and direct-to-consumer advertising is also driving market growth. As the demand for TST continues to grow, it is becoming more important for clinicians to understand how to diagnose and treat patients with low testosterone.
authors: Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA.
authors: Mohit
authors: M
authors: Khera
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000150:complications / Q000378:metabolism; D048909:Diabetes Complications / Q000150:complications / Q000378:metabolism; D005058:Eunuchism / Q000188:drug therapy* / Q000378:metabolism; D020249:Hormone Replacement Therapy; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000453:epidemiology; D008297:Male; D010024:Osteoporosis / Q000150:complications / Q000378:metabolism; D011470:Prostatic Hyperplasia / Q000453:epidemiology; D011471:Prostatic Neoplasms / Q000453:epidemiology*; D012307:Risk Factors; D013739:Testosterone / Q000009:adverse effects* / Q000172:deficiency / Q000627:therapeutic use*
chemical_list: D013739:Testosterone
references: Aging Male. 2008 Jun;11(2):57-61
references: 18570056
references: Asian J Androl. 2015 Mar-Apr;17(2):206-11
references: 25652633
references: Int J Impot Res. 2009 Jan-Feb;21(1):1-8
references: 18923415
references: Exp Clin Endocrinol Diabetes. 2009 Jan;117(1):38-43
references: 18523930
references: J Androl. 2009 Sep-Oct;30(5):477-94
references: 19342698
references: Aging Male. 2011 Mar;14(1):53-8
references: 21171937
references: JAMA. 2013 Nov 6;310(17):1829-36
references: 24193080
references: Eur Urol. 2014 Jan;65(1):115-23
references: 24011426
references: PLoS One. 2014;9(1):e85805
references: 24489673
references: Asian J Androl. 2015 Mar-Apr;17(2):212-6
references: 25337845
references: Asian J Androl. 2015 Mar-Apr;17(2):197-200
references: 25337850
references: Asian J Androl. 2015 Mar-Apr;17(2):177-86
references: 25532575
references: J Clin Endocrinol Metab. 2001 Feb;86(2):724-31
references: 11158037
references: Asian J Androl. 2015 Mar-Apr;17(2):201-5
references: 25578932
references: Asian J Androl. 2015 Mar-Apr;17(2):187-91
references: 25652628
references: J Clin Endocrinol Metab. 2004 Feb;89(2):503-10
references: 14764753
references: Asian J Androl. 2015 Mar-Apr;17(2):192-6
references: 25652634
references: Endocrinology. 1989 Aug;125(2):1000-10
references: 2502373
references: J Sex Med. 2006 Nov;3(6):1085-9
references: 17100942
references: J Androl. 2009 Jan-Feb;30(1):23-32
references: 18772488